Clinical Trial Update: Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older [Phase 1]

View source ↗

Summary

Phase 1 trial of MLN4924 (pevonedistat) in combination with azacitidine in treatment-naive patients aged 60 and older with acute myeloid leukemia has completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• MLN4924 (pevonedistat)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Acute Myelogenous Leukemia | Phase 1 | Status: COMPLETED | Results posted: 2020-03-03